- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 38/52 - Isomérases (5)
Détention brevets de la classe A61K 38/52
Brevets de cette classe: 121
Historique des publications depuis 10 ans
|
14
|
16
|
12
|
11
|
9
|
14
|
8
|
12
|
6
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Modernatx, Inc. | 1281 |
10 |
| Seattle Children's Research Institute | 17 |
8 |
| Vitamerica UG (haftungsbeschrankt) | 8 |
7 |
| The Regents of the University of California | 20574 |
5 |
| Rowan University | 191 |
4 |
| Translate bio, Inc. | 413 |
4 |
| The Board of Trustees of the Leland Stanford Junior University | 6600 |
3 |
| DSM IP Assets B.V. | 5432 |
3 |
| Baylor College of Medicine | 997 |
3 |
| Allogene Therapeutics, Inc. | 161 |
3 |
| President and Fellows of Harvard College | 6045 |
2 |
| The Broad Institute, Inc. | 1937 |
2 |
| Poseida Therapeutics, Inc. | 164 |
2 |
| Rijksuniversiteit Groningen | 311 |
2 |
| SCIOTEC Diagnostic Technologies GmbH | 4 |
2 |
| Spark Therapeutics, Inc. | 178 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2973 |
2 |
| University of Delaware | 372 |
2 |
| Vitamerica UG | 2 |
2 |
| Obsidian Therapeutics, Inc. | 76 |
2 |
| Autres propriétaires | 51 |